secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001193125-23-060828
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio reports positive Phase 2 Cohort 5 data for infigratinib in achondroplasia; mean AHV increase +3.03 cm/yr
--------------------------------------------------------------------------------

- Mean change from baseline in annualized height velocity (AHV) at six months: +3.03 cm/yr (p=0.0022) in Cohort 5 (0.25 mg/kg daily).
- 80% of 10 children with six-month visits were responders (≥25% increase in AHV); mean change among responders +3.81 cm/yr.
- No treatment-related adverse events in Cohort 5; no SAEs or discontinuations in any cohort.
- BridgeBio has started enrolling children in a Phase 3 trial and plans to initiate development for hypochondroplasia.
- Median absolute AHV reached 7.6 cm/yr, beyond the 99th percentile for achondroplasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523060828/0001193125-23-060828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312523060828/d467337d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-060828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer